Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.30 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.30 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL745985 | 1.00 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL505726 | 1.00 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL4609252 | 1.00 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL841973 | 1.00 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL18555595 | 1.00 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL18957048 | 1.00 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL4627762 | 0.85 | GABRR1 (0.39) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL3620776 | 0.85 | GABRR1 (0.39) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL3620778 | 0.85 | GABRR1 (0.39) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL19816446 | 0.85 | GABRR1 (0.39) | GABRR1SLC6A12SLC6A11SLC6A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4360713-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | F. Hoffmann-La Roche AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| US-20240116926-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-04-11 | — | — | US | disclosed |
| EP-3853220-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN LA ROCHE (CH) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023209086-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2023-09-21 | — | — | US | disclosed |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-08-15 | — | — | US | disclosed |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| EP-4169575-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | Sato Pharmaceutical Co., Ltd. (JP) | 2023-04-26 | — | — | EP | disclosed |
| EP-4126839-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | Dong-A ST Co., Ltd. (KR) | 2023-02-08 | — | — | EP | disclosed |
| US-6992087-B2 | Substituted aryl 1,4-pyrazine derivatives | PFIZER INC (US) | 2006-01-31 | — | — | US | disclosed |
| US-6964965-B2 | Substituted pyrazine derivatives | PHARMACIA & UPJOHN (US) | 2005-11-15 | — | — | US | disclosed |
| US-20050038040-A1 | Compounds as CRF1 receptor antagonists | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| EP-1499599-A1 | SUBSTITUTED PYRAZINE DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040242587-A1 | Pyrrolo[1,2-b]pyridazine compounds | PFIZER INC | 2004-12-02 | — | — | US | disclosed |
| WO-2004099201-A1 | COMPOUNDS AS CRF1 RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004099213-A2 | PYRROLO (1,2-B) PYRIDAZINE COMPOUNDS AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040053941-A1 | Substituted pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-18 | — | — | US | disclosed |
| WO-2003091225-A1 | SUBSTITUTED PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053941-A1 | Substituted pyrazine derivatives | CRHR1, CRHR2, CRH | GABRR1 463/4885SLC6A12 3405/4885SLC6A11 677/4885 |
| US-20240116926-A1 | HETEROAROMATIC COMPOUNDS | CYP1B1, CYP2D6, CYP1A1 | GABRR1 3568/4885SLC6A12 3690/4885SLC6A11 2147/4885 |
| US-20050038040-A1 | Compounds as CRF1 receptor antagonists | CRHR1, CRHR2, CRH | GABRR1 324/4885SLC6A12 800/4885SLC6A11 178/4885 |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | ABL1, TP53, JAK1 | GABRR1 2577/4885SLC6A12 4404/4885SLC6A11 4597/4885 |
| US-20040242587-A1 | Pyrrolo[1,2-b]pyridazine compounds | CRHR1, CRHR2, CRH | GABRR1 522/4885SLC6A12 860/4885SLC6A11 282/4885 |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ABL1, TP53, JAK1 | GABRR1 2577/4885SLC6A12 4404/4885SLC6A11 4597/4885 |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | HPGDS, PTGS1, PTGIS | GABRR1 1461/4885SLC6A12 4551/4885SLC6A11 3292/4885 |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | AHR, ARNT, AIPL1 | GABRR1 4081/4885SLC6A12 4800/4885SLC6A11 4691/4885 |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | HTR2C, HTR4, HTR5A | GABRR1 604/4885SLC6A12 2187/4885SLC6A11 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.